Drug profile · INN
pirbuterol acetate
MAXAIR
pirbuterol acetate (MAXAIR) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — pirbuterol acetate
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pirbuterol acetate (MAXAIR) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor agonist
Primary target: Beta-2 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pirbuterol acetate?
pirbuterol acetate (MAXAIR) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for pirbuterol acetate?
MAXAIR is a marketed brand name for pirbuterol acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pirbuterol acetate?
pirbuterol acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.